-
Product Insights
NewPulmonary Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Pulmonary Tuberculosis Clinical Trial Report Overview A total of 504 pulmonary tuberculosis clinical trials were conducted as of April 2024. The pulmonary tuberculosis clinical trial report provides a comprehensive understanding of the pulmonary tuberculosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · North America · ...
-
Sector Analysis
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Methicillin-Resistant Staphylococcus Aureus (MRSA) Clinical Trial Report Overview A total of 418 MRSA clinical trials were conducted as of January 2024. The MRSA clinical trial report provides a comprehensive understanding of the MRSA clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe · ...
-
Product Insights
Klebsiella Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Escherichia coli Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Escherichia coli Infections - Drugs In Development, 2023’, provides an overview of the Escherichia coli Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Klebsiella pneumoniae Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella pneumoniae Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tetanus – Drugs In Development, 2023
Global Markets Direct’s, ‘Tetanus - Drugs In Development, 2023’, provides an overview of the Tetanus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pertussis (Whooping Cough) – Drugs In Development, 2023
Global Markets Direct’s, ‘Pertussis (Whooping Cough) - Drugs In Development, 2023’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Resistant Pseudomonas aeruginosa Infections - Drugs In Development, 2023’, provides an overview of the Resistant Pseudomonas aeruginosa Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...